Lung Cancer News and Research

Latest Lung Cancer News and Research

Researchers use two new methods to detect levels of ALK protein expression in NSCLC

The implementation of personalized health care in cancer relies on the identification and characterization of cancer biomarkers and the availability of accurate detection systems and therapies for those biomarkers.

2 Jul 2013

SBRT treatment safe and effective for stage I NSCLC, study finds

Stereotactic body radiotherapy is considered the treatment of choice for early-stage non-small-cell lung cancer if patients are inoperable because of additional medical conditions.

2 Jul 2013

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

1 Jul 2013

Study shows autophagy blockers play a role in treatment of non-small-cell lung cancer

New research from Rutgers Cancer Institute of New Jersey, Princeton University and other collaborators suggests that inactivation of an essential gene responsible for the cell survival process known as autophagy can suppress the growth of non-small-cell lung cancer tumors and render them more benign.

1 Jul 2013

Case Comprehensive Cancer Center secures "outstanding" rating from NCI

The Case Comprehensive Cancer Center (CCCC) again demonstrated the compelling power of partnership in securing an overall rating of "outstanding" and a five-year renewal of its grant from the National Cancer Institute (NCI).

28 Jun 2013

Low-molecular-weight PAHs promote conditions for cancer growth

Tobacco smoke, diesel exhaust and oil combustion carry polycyclic aromatic hydrocarbons - PAHs that are known to cause cancer. But of these PAHs, the obviously dangerous high-molecular-weight PAHs like benzo[a]pyrene (BaP) have received the vast majority of research attention.

26 Jun 2013

Immunohistochemistry could be a reliable and cost-effective diagnostic approach for lung cancer

ALK rearrangement has been demonstrated to be a potent oncogenic driver and a promising therapeutic target in non-small cell lung cancer (NSCLC). It defines a distinct molecular subset of NSCLC, in particular adenocarcinoma that can benefit by the treatment of ALK-inhibitors.

26 Jun 2013

Pretreatment PET staging of LS-SCLC associated with improved survival

Each year, 13 percent of all newly diagnosed lung cancer patients are diagnosed with small-cell lung cancer (SCLC). Approximately 39 percent of patients with SCLC are diagnosed with limited-stage disease, meaning the cancer is only present in one lung, but may have spread to lymph nodes or tissue between the lungs.

26 Jun 2013

Sarah Cannon Research Institute opens enrollment in Phase I clinical study with MORAb-066

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that the Sarah Cannon Research Institute in Nashville, Tennessee has opened enrollment in a Phase I clinical study with MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small cell lung cancer (adenocarcinoma) malignancies.

26 Jun 2013

Lung cancer in women more frequently associated with EGFR mutation and ER expression

The incidence of lung cancer in women affects an estimated 516,000 women worldwide, of which 100,000 are in the United States and 70,000 in Europe. Until now, lung cancers occurring in women have been treated similarly to lung cancers in men. However, numerous studies have highlighted different characteristics of lung cancer in women.

26 Jun 2013

State highlights: Calif. eyes health care for immigrants; New scrutiny for N.Y. home health firms; Examining Ore. insurers' choice on smokers

When Congress passed President Obama's health care overhaul, a critical compromise provision was that immigrants living in the United States illegally would not be allowed access to publicly subsidized health insurance.

25 Jun 2013

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Sorrento Therapeutics, Inc. and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq) and IG-004 (TOCOSOL paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine and the European Technology Platform on Nanomedicine in Basel, Switzerland on June 23 - 26.

21 Jun 2013

Aspirin slows accumulation of DNA mutations in abnormal cells, points UCSF scientist

Aspirin is known to lower risk for some cancers, and a new study led by a UC San Francisco scientist points to a possible explanation, with the discovery that aspirin slows the accumulation of DNA mutations in abnormal cells in at least one pre-cancerous condition.

19 Jun 2013

Research findings may pave way for new strategy to combat lung cancer

Recent research has shown that cancer cells have a much different - and more complex - metabolism than normal cells. Now, scientists at The University of Texas at Dallas have found that exploiting these differences might provide a new strategy to combat lung cancer.

19 Jun 2013

Targeting SALL4 protein with druglike molecules could halt tumor growth, say researchers

Harvard Stem Cell Institute researchers have identified in the most aggressive forms of cancer a gene known to regulate embryonic stem cell self-renewal, beginning a creative search for a drug that can block its activity.

18 Jun 2013

Pyrvinium pamoate inhibits drug-resistant prostate cancer

A new drug called pyrvinium pamoate inhibits aggressive forms of prostate cancer that are resistant to standard drugs, according to a study conducted in an animal model. The results will be presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

18 Jun 2013

AIFA approves pricing and reimbursement conditions for InterMune's Esbriet

InterMune, Inc. today announced that the Board of the Italian Drug Agency has approved the pricing and reimbursement conditions for Esbriet (pirfenidone), and that the agreement has been published in the Official Gazette, the official journal of the government of Italy.

15 Jun 2013

MemoryShape Breast Implants receive FDA approval

The U.S. Food and Drug Administration today approved the MemoryShape Breast Implant to increase breast size (augmentation) for use in women at least 22 years old and to rebuild breast tissue (reconstruction) in women of any age.

15 Jun 2013

Smartphone users can now diagnose diabetes or lung cancer quickly and effectively by simply breathing

Today's technological innovation enables smartphone users to diagnose serious diseases such as diabetes or lung cancer quickly and effectively by simply breathing into a small gadget, a nanofiber breathing sensor, mounted on the phones.

12 Jun 2013

GiveForward partners with Lung Cancer Alliance to support families affected by lung cancer

GiveForward, a crowdfunding leader helping families and friends raise money for a loved one's medical bills, is pleased to announce a new partnership with the Lung Cancer Alliance, a non-profit organization dedicated solely to helping individuals living with and at risk for lung cancer.

12 Jun 2013

Lung Cancer News and Research

Latest Lung Cancer News and Research

Researchers use two new methods to detect levels of ALK protein expression in NSCLC

SBRT treatment safe and effective for stage I NSCLC, study finds

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Study shows autophagy blockers play a role in treatment of non-small-cell lung cancer

Case Comprehensive Cancer Center secures "outstanding" rating from NCI

Low-molecular-weight PAHs promote conditions for cancer growth

Immunohistochemistry could be a reliable and cost-effective diagnostic approach for lung cancer

Pretreatment PET staging of LS-SCLC associated with improved survival

Sarah Cannon Research Institute opens enrollment in Phase I clinical study with MORAb-066

Lung cancer in women more frequently associated with EGFR mutation and ER expression

State highlights: Calif. eyes health care for immigrants; New scrutiny for N.Y. home health firms; Examining Ore. insurers' choice on smokers

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Aspirin slows accumulation of DNA mutations in abnormal cells, points UCSF scientist

Research findings may pave way for new strategy to combat lung cancer

Targeting SALL4 protein with druglike molecules could halt tumor growth, say researchers

Pyrvinium pamoate inhibits drug-resistant prostate cancer

AIFA approves pricing and reimbursement conditions for InterMune's Esbriet

MemoryShape Breast Implants receive FDA approval

Smartphone users can now diagnose diabetes or lung cancer quickly and effectively by simply breathing

GiveForward partners with Lung Cancer Alliance to support families affected by lung cancer

The ultimate guide to lung research tools and protocols eBook

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Newsletters you may be interested in